Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated April 10, 2018, reports on a significant capital raising event by Cellectis S.A., a French biopharmaceutical company. The filing details the execution of an Underwriting Agreement entered into on April 4, 2018, with Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., and Barclays Capital Inc.
Key Financial Metrics
- Offering Size: 5,646,000 ordinary shares in the form of American Depositary Shares (ADSs).
- Offering Price: $31.00 per ADS.
- Net Proceeds: Approximately $163.7 million after deducting underwriting discounts, commissions, and estimated expenses.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 846,900 ADSs.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these operational metrics as this is a transactional filing rather than a periodic financial report.
Material Changes
The primary material change is the increase in the company's cash liquidity resulting from the equity offering. The transaction was executed pursuant to an effective shelf registration statement on Form F-3 filed on March 31, 2017. The offering was expected to close on April 10, 2018, subject to customary closing conditions.
Outlook, Risks, and Contingencies
The filing outlines standard contractual obligations, including customary representations, warranties, and covenants. The Company agreed to indemnify the underwriters against certain liabilities under the Securities Act of 1933 or to contribute to payments required by the underwriters. No specific operational risks or future guidance were detailed in this specific excerpt beyond the closing of the transaction.
Key Facts for Investor Verification
- Confirm the final closing date of the offering and whether the over-allotment option was exercised.
- Verify the actual net proceeds received after all final expenses are accounted for.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods or restrictive covenants.
- Check subsequent filings to determine how the $163.7 million in proceeds are allocated (e.g., R&D, clinical trials, general corporate purposes).